Alfasigma

Alfasigma is an Italian multinational pharmaceutical company founded in 2015 through the merger of Alfa Wassermann and Sigma-Tau. It specializes in gastroenterology and vascular diseases, establishing itself as a leader in these therapeutic areas. The company operates in over 100 countries and has reported consolidated revenues exceeding one billion euros as of 2021. Alfasigma's product portfolio includes pharmaceuticals, medical devices, and food supplements. In 2022, it expanded its capabilities by acquiring Sofar, enhancing its offerings in drugs, medical devices, and supplements. Additionally, Alfasigma serves as a contract manufacturing organization, providing manufacturing services to other pharmaceutical companies. This dual role underscores its comprehensive capabilities in the pharmaceutical sector, catering to diverse medical needs globally.